FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE
FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE · ONE OF JUST 8 NATIONWIDE
FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE
FLORIDA'S ONLY JOINT COMMISSION-ACCREDITED URGENT CARE · ONE OF JUST 8 NATIONWIDE
Tesamorelin and sermorelin are both growth hormone-releasing peptides used in body composition and longevity protocols. They are often grouped together but they have different mechanisms, different FDA statuses, different indications, different potency, and different side-effect profiles. This guide is a physician-led comparison built for patients deciding between them.
Sermorelin is a GHRH (growth hormone-releasing hormone) analog containing the first 29 amino acids of human GHRH. It stimulates the pituitary's natural pulsatile release of growth hormone. Half-life is short (~10-20 minutes). Effect mimics the body's own GHRH signaling.
Tesamorelin is a synthetic GHRF (growth hormone-releasing factor) analog. It has a modified structure that resists enzymatic degradation, giving it a longer half-life and more sustained action. Effect on growth hormone release is more pronounced and longer-lasting than sermorelin.
Practical difference: sermorelin is closer to physiological signaling; tesamorelin is more potent. Sermorelin is often the first-line choice for patients new to growth hormone-releasing peptides; tesamorelin is reserved for patients with stronger clinical indications.
Sermorelin was previously FDA-approved (Geref) for pediatric growth hormone deficiency. Geref was discontinued in 2008. Sermorelin remains available through licensed US 503A and 503B compounding pharmacies under physician prescription. It is not currently FDA-approved for any specific adult indication; off-label use in adult body composition and longevity protocols is common.
Tesamorelin (Egrifta, Egrifta SV) is FDA-approved for the treatment of HIV-associated lipodystrophy (excess abdominal fat in HIV-positive patients on antiretroviral therapy). Off-label use in patients with metabolic syndrome and visceral adiposity is common in performance medicine practice.
Sermorelin is appropriate for: adults with documented low IGF-1, body composition support, lean mass preservation during weight loss, sleep quality optimization, recovery from training cycles. Patients new to growth hormone-releasing peptides often start with sermorelin.
Tesamorelin is appropriate for: HIV-associated lipodystrophy (FDA-approved), patients with metabolic syndrome and visceral adiposity, patients who have plateaued on sermorelin and need a more potent intervention, advanced longevity stacks where stronger growth hormone effect is desired.
For most patients in the TrufaMED performance medicine program, sermorelin is the first-line choice. Tesamorelin is selected for specific clinical profiles where the more potent intervention is warranted.
Both peptides share a common side-effect profile: injection-site reactions, occasional flushing, transient fluid retention (more common with tesamorelin), and rare arthralgias. Both require IGF-1 monitoring to avoid supraphysiological growth hormone levels. Both are contraindicated in patients with active malignancy, recent cancer history, or severe cardiovascular disease.
Tesamorelin specifically has additional considerations from its FDA prescribing information including injection-site reactions in 25-30% of patients in clinical trials. Sermorelin generally has a milder local-reaction profile due to lower potency.
The TrufaMED program screens for contraindications during the consultation and orders baseline labs before any prescription. Patients are not started on either peptide without negative malignancy screening, IGF-1 baseline, and metabolic panel review.
The selection between sermorelin and tesamorelin happens during the physician consultation, after labs return. Factors that influence the decision include: baseline IGF-1 (lower IGF-1 may favor sermorelin to start), metabolic syndrome status (favors tesamorelin), visceral adiposity (favors tesamorelin), prior response to growth hormone-releasing peptides (helps calibrate dose), and patient tolerance preferences.
Most patients new to peptide therapy start with sermorelin at a conservative dose, with monthly review and dose titration. Patients who plateau or who present with stronger metabolic indications transition to tesamorelin under physician guidance.
For program details and to start a consultation, see Performance Medicine Miami.
Mechanism and potency. Sermorelin is a GHRH analog that mimics the body's natural growth hormone signaling. Tesamorelin is a more potent GHRF analog with a longer half-life. Tesamorelin has stronger effects on growth hormone release and is FDA-approved for HIV-associated lipodystrophy; sermorelin is used off-label for adult body composition and longevity protocols.
Neither is a primary weight loss medication. For pure weight loss, FDA-approved GLP-1 medications (tirzepatide, semaglutide) produce significantly greater weight reduction. Tesamorelin can reduce visceral adipose specifically and is used in patients with visceral adiposity. Sermorelin supports lean mass preservation during weight loss but is not itself a fat-loss agent.
Yes, for HIV-associated lipodystrophy. Off-label use in metabolic syndrome and visceral adiposity is common in performance medicine practice but is not separately FDA-approved.
Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency; that brand was discontinued in 2008. Sermorelin remains available through licensed US 503A and 503B compounding pharmacies under physician prescription, used off-label for adult body composition and longevity protocols.
Tesamorelin has a higher rate of injection-site reactions (25-30% in clinical trials) and is more likely to cause transient fluid retention due to its higher potency. Sermorelin generally has a milder local-reaction profile. Both require IGF-1 monitoring to avoid supraphysiological growth hormone levels.
Combining two GHRH/GHRF analogs is not standard practice and increases the risk of supraphysiological growth hormone levels and side effects. Typical clinical practice uses one at a time, with selection based on the patient's labs, history, and goals.
Most protocols run 3 to 6 months minimum with quarterly lab review. Patients who respond well may continue maintenance protocols long-term under physician supervision. Continuous use without cycling, IGF-1 monitoring, and dose review is not appropriate practice.
Yes. Both growth hormone-releasing peptides are on the World Anti-Doping Agency (WADA) banned substances list. Athletes subject to WADA or sport-federation testing should not use these peptides without explicit medical exemption documentation.
Yes. Required baseline labs include comprehensive metabolic panel, lipid panel, IGF-1, free testosterone, thyroid panel, fasting insulin, and vitamin D. Some protocols also require pituitary function testing. Quarterly IGF-1 monitoring is required during treatment.
Both are dispensed through licensed US 503A or 503B compounding pharmacies. Pharmacy sourcing is disclosed transparently before any prescription is written. We do not source from unregulated international vendors.
Pricing depends on peptide selection, dose, and concierge tier. The TrufaMED program is billed monthly as part of the concierge membership and includes peptide, physician visits, labs, and monitoring. Pricing is shared during your consultation.
Message us on WhatsApp at +1 (305) 842-9801. We schedule a physician consultation within 24 to 48 hours. The consultation reviews your goals, prior peptide experience, and any contraindications. Labs are ordered same-day if you are appropriate for the program.
To start a consultation with the TrufaMED concierge program, message us on WhatsApp.
Message us on WhatsApp+1 (305) 842-9801 · 9445 Harding Ave, Surfside, FL 33154
Serving These Areas
Copyright © 2026 TrufaMED Urgent Care
